Syndax reveals 12 abstracts on Revuforj's strong leukemia treatment data for EHA 2026 conference

Syndax Pharmaceuticals announced 12 abstracts on Revuforj (revumenib) accepted for presentation at the EHA 2026 Congress, highlighting its efficacy across various acute leukemia subtypes and treatment stages. Data include real-world outcomes, post-transplant maintenance, and combination therapies showing deep responses and favorable tolerability. These findings reinforce Syndax's leadership in menin inhibition and support ongoing pivotal trials aimed at transforming treatment for over half of AML patients. The presentations will provide critical insights into Revuforj's potential to improve leukemia care.